SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System

Lancet Diabetes Endocrinol. 2017 Sep;5(9):680-681. doi: 10.1016/S2213-8587(17)30257-7. Epub 2017 Jul 18.

Authors

Gian Paolo Fadini¹, Angelo Avogaro²

Affiliations

¹ Division of Metabolic Diseases, Department of Medicine, University of Padova, 35128 Padova, Italy. Electronic address: gianpaolo.fadini@unipd.it.
² Division of Metabolic Diseases, Department of Medicine, University of Padova, 35128 Padova, Italy.

PMID: 28733172
DOI: 10.1016/S2213-8587(17)30257-7

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Amputation, Surgical / statistics & numerical data*
Canagliflozin / adverse effects*
Cardiovascular Diseases / etiology
Clinical Trials as Topic
Diabetes Mellitus, Type 2 / complications*
Diabetes Mellitus, Type 2 / surgery*
Humans
Hypoglycemic Agents / adverse effects*
Risk Factors
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors*
United States
United States Food and Drug Administration

Substances

Hypoglycemic Agents
SLC5A2 protein, human
Sodium-Glucose Transporter 2
Sodium-Glucose Transporter 2 Inhibitors
Canagliflozin